Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 03, 2015 11:36 PM ET


Company Overview of EpiCept Corporation

Company Overview

As of August 25, 2013, EpiCept Corporation was acquired by Immune Pharmaceuticals Ltd., in a reverse merger transaction. EpiCept Corporation, a specialty pharmaceutical company, focuses on the clinical development and commercialization of pharmaceutical products for the treatment of pain and cancer. The company develops AmiKet, a prescription topical analgesic cream that has completed Phase II clinical trials for the treatment of peripheral neuropathies. It also develops Azixa, an apoptosis inducer that is in Phase II clinical development for the treatment of brain cancer. In addition, the company is developing crolibulin, a novel small molecule vascular disruption agent and apoptosis induce...

777 Old Saw Mill River Road

Tarrytown, NY 10591

United States

Founded in 1993

4 Employees





Key Executives for EpiCept Corporation

EpiCept Corporation does not have any Key Executives recorded.

EpiCept Corporation Key Developments

EpiCept Corporation(OM:EPCT) dropped from OMX Nordic All-Share Index

EpiCept Corporation will be removed from OMX Nordic All-Share Index.

EpiCept Corporation(OM:EPCT) dropped from OMX Nordic Small Cap Index

EpiCept Corporation will be removed from OMX Nordic Small Cap Index.

Immune Pharmaceuticals Inc. Announces Management Changes

Immune Pharmaceuticals Inc. announced the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation. Immune Pharmaceuticals Inc. also announced that, in connection with the closing of the merger, the composition of the company's board of directors has changed and increased to seven persons. Daniel Teper, the company's Chief Executive Officer, has joined the board of directors as Chairman. David Sidransky, Professor of Oncology at the Johns Hopkins School of Medicine, has been appointed Vice Chairman. Ana Stancic has been named the chairperson of the company's audit committee. Isaac Kobrin, Herve de Kergrohen, and Pierre Albouy have also been named to the company's board. Robert Cook, EpiCept's previous interim President and CEO, retains his position on the board and has become the company's Chief Financial Officer. Alan Dunton, previous non-executive chairman of EpiCept, Robert Savage, and Keith Brownlie have resigned their positions, effective as of the closing date of the merger August 26, 2013.

Similar Private Companies By Industry

Company Name Region
SGM Biotech, Inc. United States
Semma Therapeutics, Inc. United States
Compass Therapeutics LLC United States
Amgen Manufacturing, Limited United States
TGG Medical Transitory, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EpiCept Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at